With COVID-19 vaccines proving highly effective and safe, mRNA technology from Pfizer-BioNTech and Moderna is sparking a breakthrough in cancer research.
In November 2020, Pfizer and BioNTech announced their mRNA vaccine was 90% effective against SARS-CoV-2. It rolled out in the UK shortly after and in the US soon thereafter. The companies aimed to produce 50 million doses by end-2020 and 1.3 billion in 2021. Moderna sought European approval on January 12, 2021.
These vaccines use lipid nanoparticle capsules to deliver mRNA fragments encoding the SARS-CoV-2 spike protein into cells. Cells read this mRNA, produce the protein, and train the immune system to recognize and neutralize the virus.
A December 13, 2020, Bloomberg article highlighted mRNA's potential beyond COVID-19, including cancer and other diseases. Decades of lab work, accelerated by pandemic funding, have validated this approach.
Government billions fueled rapid progress, making COVID-19 the first major real-world test of mRNA medicine.
Moderna CEO Uğur Şahin, with 20 years in cancer research, sees COVID vaccines building on that foundation. He predicts early mRNA cancer treatments in 2-3 years, teaching the body to target cancer cells selectively. Results are mixed—disappointing for colorectal cancer but promising for head and neck cancers.
Beyond cancer, mRNA holds promise for improved flu vaccines, heart conditions, cystic fibrosis, cytomegalovirus, and even HIV. While optimistic, these advances require time and further validation.
